Taken together, the results above highlight the possibility that KEAP1‐wild type tumors are associated with higher tumor immunity and, therefore, may be sensitive to immunotherapy, providing a new treatment modality and biomarker for those LUADs with KEAP1‐wild type. The gene discussed is KEAP1; the disease is neoplasm.